全文获取类型
收费全文 | 97014篇 |
免费 | 5696篇 |
国内免费 | 5207篇 |
专业分类
耳鼻咽喉 | 615篇 |
儿科学 | 1928篇 |
妇产科学 | 1941篇 |
基础医学 | 8409篇 |
口腔科学 | 2519篇 |
临床医学 | 10211篇 |
内科学 | 14315篇 |
皮肤病学 | 735篇 |
神经病学 | 3032篇 |
特种医学 | 4852篇 |
外国民族医学 | 12篇 |
外科学 | 8155篇 |
综合类 | 19333篇 |
现状与发展 | 6篇 |
一般理论 | 12篇 |
预防医学 | 9366篇 |
眼科学 | 1950篇 |
药学 | 8182篇 |
32篇 | |
中国医学 | 6719篇 |
肿瘤学 | 5593篇 |
出版年
2024年 | 101篇 |
2023年 | 585篇 |
2022年 | 1260篇 |
2021年 | 1722篇 |
2020年 | 1362篇 |
2019年 | 1160篇 |
2018年 | 1333篇 |
2017年 | 1236篇 |
2016年 | 1323篇 |
2015年 | 1759篇 |
2014年 | 2251篇 |
2013年 | 2409篇 |
2012年 | 3530篇 |
2011年 | 6769篇 |
2010年 | 4105篇 |
2009年 | 2949篇 |
2008年 | 3784篇 |
2007年 | 3691篇 |
2006年 | 3679篇 |
2005年 | 4694篇 |
2004年 | 8932篇 |
2003年 | 8222篇 |
2002年 | 6614篇 |
2001年 | 5321篇 |
2000年 | 3493篇 |
1999年 | 4064篇 |
1998年 | 2801篇 |
1997年 | 2555篇 |
1996年 | 1655篇 |
1995年 | 1434篇 |
1994年 | 1461篇 |
1993年 | 2070篇 |
1992年 | 1837篇 |
1991年 | 1593篇 |
1990年 | 1256篇 |
1989年 | 1024篇 |
1988年 | 769篇 |
1987年 | 668篇 |
1986年 | 626篇 |
1985年 | 326篇 |
1984年 | 181篇 |
1983年 | 109篇 |
1982年 | 81篇 |
1981年 | 78篇 |
1980年 | 74篇 |
1979年 | 114篇 |
1978年 | 73篇 |
1977年 | 68篇 |
1975年 | 78篇 |
1974年 | 74篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
中国抗癌协会神经内分泌肿瘤专业委员会 《中国癌症杂志》2022,32(6):545-579
神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一类起源于肽能神经元和神经内分泌细胞,具有神经内分泌分化并表达神经内分泌标志物的少见肿瘤,可发生于全身各处,以肺及胃肠胰NEN(gastroenteropancreatic neuroendocrine neoplasm, GEP-NEN)最常见。国内外研究数据均提示,NEN的发病率在不断上升。美国流行病学调查结果显示,与其他类型肿瘤相比,NEN的发病率上升趋势更为显著。中国抗癌协会神经内分泌肿瘤专委会在现有循证医学证据基础上,结合已有国内外指南和共识,制订了首版中国抗癌协会神经内分泌肿瘤诊治指南,为临床工作者提供参考。 相似文献
3.
4.
Xiumei Jiang Xiaowei Zhang Patrick Gray Jiwen Zheng Timothy R. Croley Peter P. Fu 《journal of environmental science and health part c-environmental carcinogenesis & ecotoxicology reviews》2019,37(2):116-131
Gold nanoparticles (Au NPs) hold great promise in food, industrial and biomedical applications due to their unique physicochemical properties. However, influences of the gastrointestinal tract (GIT), a likely route for Au NPs administration, on the physicochemical properties of Au NPs has been rarely evaluated. Here, we investigated the influence of GIT fluids on the physicochemical properties of Au NPs (5, 50, and 100?nm) and their implications on intestinal epithelial permeability in vitro. Au NPs aggregated in fasted gastric fluids and generated hydroxyl radicals in the presence of H2O2. Cell studies showed that GIT fluids incubation of Au NPs affected the cellular uptake of Au NPs but did not induce cytotoxicity or disturb the intestinal epithelial permeability. 相似文献
5.
6.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
7.
8.
9.